Fuda Cancer Hospital
| China | Turki | Austria | |
| Transplantasi sumsum tulang | dari $55,000 | dari $36,000 | dari $140,000 |
| Terapi sinar proton | dari $36,500 | dari $70,000 | dari $80,000 |
| Sistem Robotik Da Vinci | dari $24,500 | dari $9,500 | dari $22,000 |
| Reseksi tiroid | dari $8,200 | dari $3,500 | dari $10,000 |
| Radioterapi | dari $9,500 | dari $6,000 | dari $12,000 |
Bookimed tidak menambah biaya tambahan dalam harga perawatan Onkologi. Tarif berasal dari daftar harga resmi klinik. Anda membayar langsung di klinik saat tiba di negara tujuan untuk perawatan Anda.
Bookimed berkomitmen pada keselamatan Anda. Kami hanya bekerja dengan institusi medis yang menjaga standar internasional tinggi dalam perawatan Onkologi dan memiliki izin yang dibutuhkan untuk melayani pasien internasional di seluruh dunia.
Bookimed menawarkan bantuan ahli gratis. Koordinator medis pribadi mendukung Anda sebelum, selama, dan setelah perawatan, menyelesaikan semua masalah Anda. Anda tidak pernah sendirian dalam perjalanan perawatan Onkologi Anda.
Dr. Luan Tianyan, MD, is Head of Oncology. He was recruited to Hainan Province as a high-level talent. He is a visiting scholar at the Dana-Farber Cancer Institute (USA). He is also Director of the Clinical Research Office at Bozheng Hengda International Hospital. He serves on the standing committees of the Clinical Research Management Committee (Southern Oncology Clinical Research Association), the Immunotherapy Committee (Hainan Provincial Anti-Cancer Association), and the Hainan Province Drug Research Committee.
He has more than 20 years of oncology practice. He provides individualized, comprehensive care for gastrointestinal tumors, lung cancer, and breast cancer. He focuses on pain management, palliative care, and psychological support in advanced cancer. He also works on the clinical use and study of tumor immunotherapy, including personalized mRNA vaccines and CAR-T therapy. He develops and applies proprietary drugs and related technologies.
Dr. Zhang Yanjun is a chief radiation oncologist at Jinshazhou Hospital in Guangzhou. He oversees pediatric and adult cases with a focus on neuro-oncology and stereotactic radiotherapy. Dr. Zhang completed two international fellowships at prominent cancer centers in the United States. He sits on the Executive Committee of the World Association of Chinese Oncology Physicians.
Dr. Chen Binglai is a biological immunology expert (MD). He holds a PhD in Medicine from Central South University, with a focus on genetics and integrated TCM and Western medicine. He completed postdoctoral training at New York University and the University of Bologna. He is a visiting professor at Zhongshan Hospital, Fudan University.
He is affiliated with the Shanghai Pujiang Talent Program and the Yangpu District 3310 Talent Program. He leads the innovation project “Cancer Treatment Based on Cell Culture Technology,” supported by the Pujiang Program.
He has years of oncology practice and extensive experience in treating malignant tumors. His work focuses on the clinical use and research of CAR-T, NK cell, and stem cell therapies. He uses the Lecheng pilot program to advance clinical translation in China and to offer personalized treatment plans.
Hampir 10.000 bedah beku (cryosurgery) telah dilakukan – Prof. Niu Lizhi memimpin program onkologi invasif minimal di Rumah Sakit Kanker Fuda.
Pusat onkologi Tiongkok mematuhi standar keamanan yang ketat, termasuk akreditasi dari Joint Commission International (JCI) dan sertifikasi dari Organisation of European Cancer Institutes (OECI). Institusi terkemuka seperti Fuda Cancer Hospital dan Yanda International Hospital memiliki status Kelas A Tingkat III. Ini berarti tingkat kualitas perawatan medis tertinggi di Tiongkok.
Pendapat pakar Bookimed: Data kami menunjukkan hubungan yang jelas antara jumlah pasien dan keamanan khusus. Klinik seperti Rumah Sakit Jinshazhou melayani lebih dari 680.000 pasien setiap tahun. Pusat-pusat besar sering kali berinvestasi lebih banyak dalam teknologi radioterapi yang diakui secara internasional. Mereka juga biasanya menawarkan layanan wisata medis multibahasa yang terstruktur untuk mendukung pasien asing.
Pendapat pasien: Pasien mencatat bahwa klinik-klinik terbaik menyediakan peralatan berteknologi tinggi dan perawatan keperawatan khusus. Beberapa menawarkan pendampingan penerjemah untuk mendiskusikan masalah medis secara rinci guna memastikan kejelasan semua tahap perawatan.
Onkolog Tiongkok menunjukkan keahlian internasional melalui keanggotaan global yang bergengsi, pelatihan khusus di Barat, dan penelitian klinis. Spesialis terkemuka memegang peran eksekutif dalam organisasi seperti International Society of Cryosurgery. Banyak yang menjalani fellowship di institusi papan atas di Amerika Serikat atau berpartisipasi dalam uji coba obat tahap I-IV global.
Wawasan Ahli Bookimed: Volume pasien di Tiongkok mendorong tingkat keahlian prosedural yang unik. Misalnya, Dr. Niu Lizhi di Rumah Sakit Kanker Fuda telah melakukan hampir 10.000 prosedur cryosurgery. Paparan klinis yang besar ini, dikombinasikan dengan lingkungan yang terakreditasi JCI di Yanda International, memastikan bahwa pelatihan internasional yang teoretis didukung oleh pengalaman praktis yang tak tertandingi.
Konsensus Pasien: Pasien mencatat bahwa dokter-dokter terkemuka sangat berpengetahuan dan fasilitasnya berteknologi tinggi. Mereka menghargai kemampuan untuk mengakses perawatan khusus, seperti cryoablation, sambil tinggal di kamar yang terasa seperti hotel mewah.
Waktu pemulihan setelah perawatan kanker di Tiongkok bervariasi tergantung pada jenis perawatannya. Pasien yang menjalani prosedur invasif minimal, seperti NanoKnife atau kriobedah, sering kali kembali melakukan aktivitas ringan dalam 3-7 hari. Setelah intervensi bedah, biasanya diperlukan 2-4 minggu untuk memulihkan mobilitas dasar. Perjalanan internasional umumnya aman dilakukan 10-14 hari setelah operasi.
Pendapat pakar Bookimed: Data dari pusat medis besar, seperti Rumah Sakit Internasional Yanda dan Rumah Sakit Kanker Fuda, menunjukkan preferensi untuk menggabungkan protokol internasional dengan pendekatan tradisional. Model hibrida ini sering kali berfokus pada stabilisasi kondisi yang cepat. Pasien yang memilih metode perawatan invasif minimal, seperti NanoKnife, sering melaporkan masa inap di rumah sakit yang lebih singkat. Hal ini memungkinkan mereka untuk dipulangkan ke hotel lokal lebih awal dibandingkan dengan operasi terbuka tradisional.
Pendapat pasien: Pasien mencatat bahwa disarankan untuk datang dengan cadangan waktu dua minggu untuk observasi. Mereka menekankan bahwa meskipun beberapa orang merasa siap untuk terbang 48 jam setelah perawatan non-bedah, tinggal di rumah sakit selama seminggu membantu mengatasi demam atau kelelahan yang tidak terduga.
International patients in China access oncology treatments like Chimeric Antigen Receptor T-cell (CAR-T) therapy, NanoKnife, and cryosurgery. JCI-accredited facilities in Guangzhou and Beijing provide precision radiotherapy and immunotherapy. These centres specialise in organ-preserving techniques for solid tumours and blood cancers.
Bookimed Expert Insight: China's oncology landscape is defined by its massive volume. Clinics like Fuda Cancer Hospital have treated over 30,000 international patients. This scale allows surgeons to perform rarer procedures like NanoKnife hundreds of times annually. For Australians, this frequent experience means doctors handle complex cases often seen less at home.
Patient Consensus: Patients note that Chinese clinics focus on organ preservation when other countries suggest removal. They appreciate the five-star room facilities. They also value medical staff who arrange translators to bridge communication gaps.
International oncology patients in China receive support through dedicated international departments. These teams bridge language and logistical gaps. Major centres like Fuda Cancer Hospital provide JCI-accredited care with multilingual services. Hospitals often assist with S2 medical visas and offer on-site interpreters for complex multidisciplinary team reviews.
Bookimed Expert Insight: Language support tiers vary significantly between public and private hospitals in Guangzhou and Beijing. Clinics with 4.5+ ratings, like Yanda International Hospital, typically combine international protocols with traditional Chinese medicine. These JCI-accredited facilities often provide bilingual paperwork. This is essential for patients returning to the Australian healthcare system.
Patient Consensus: Patients in China often note that native-speaking translators help communication during busy consultations. They suggest bringing translated medical records and hiring a local coordinator. This helps manage appointments, transport, and follow-up schedules comfortably.
International patients can access experimental cancer clinical trials in China if the trial design allows foreign enrolment. Many local registration trials restrict participation to Chinese citizens. However, Multi-Regional Clinical Trials (MRCTs) actively include global patients. Eligibility requires matching specific diagnostic protocols and securing an S-class medical visa.
Bookimed Expert Insight: A major advantage in China is the concentration of trial capabilities within high-volume tertiary hospitals. Xiamen Humanity Hospital manages 1,000,000 patients annually and is authorised for all drug trial phases. This volume creates a massive data pool. This often leads to faster trial progression compared to smaller Western centres.
Patient Consensus: Patients note that Chinese hospitals often offer hope when domestic treatments fail. They particularly highlight the modern equipment and five-star room facilities. Patients find that native-speaking translators help bridge the language gap. This helps doctors explain complex diagnoses in detail.
Australians seeking oncology care in China should focus on JCI-accredited facilities with international wings. Leading centres in Guangzhou and Beijing provide English-speaking coordination. They use precise therapies like NanoKnife and cryosurgery to treat complex, solid tumours.
Bookimed Expert Insight: Oncology patients often find that high-volume centres in Guangzhou specialise in organ-sparing techniques. Dr Niu Lizhi has performed nearly 10,000 cryosurgeries. This volume is rarely seen in single Australian centres. This vast clinical experience often allows doctors to treat cases considered inoperable elsewhere.
Patient consensus: Patients from Commonwealth countries highlight the modern equipment. They note that Chinese specialists often focus on saving organs rather than removal. The wards are often described as similar to five-star rooms with helpful staff. Dedicated translation support also helps to ease the journey.
Traditional Chinese Medicine (TCM) is fully integrated into oncology care in China through a dual-system framework. Hospitals such as Jinshazhou Hospital of Guangzhou University of Chinese Medicine use TCM as supportive therapy. It is used alongside chemotherapy and immunotherapy to manage side effects and bolster immune function.
Bookimed Expert Insight: Clinical data shows that the most effective integration occurs in university-affiliated hospitals. For example, Jinshazhou Hospital uses its link with Guangzhou University of Chinese Medicine to standardise herbal treatments. This helps prevent TCM from interfering with modern therapies like Keytruda or NanoKnife. Such treatments are common in these high-volume centres.
Patient Consensus: Patients in China describe TCM as a helpful way to manage side effects and improve energy. Many value having local translators and 5-star room facilities. These amenities support those receiving both modern immunotherapy and traditional herbal support.